CorMedix 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 19KA.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a global pharmaceutical company that competes with CorMedix in the development of drugs for infectious diseases, including those targeted by CorMedix's lead product, DefenCath.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. is involved in the discovery, development, manufacturing, and marketing of pharmaceuticals that directly compete with CorMedix's portfolio, especially in the antimicrobial space.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical segment, competes in the development and marketing of products that could be used in similar indications as CorMedix's, including infection prevention.
Abbott Laboratories
ABT
Mkt Cap178.76B
Abbott Laboratories offers a wide range of healthcare products that compete with CorMedix, particularly in the area of medical devices and diagnostics for infectious diseases.
AMGEN
AMGN
Mkt Cap187.56B
Amgen competes with CorMedix in the biopharmaceutical field, focusing on innovative treatments that could overlap with CorMedix's market, especially in the area of infection control.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas that compete with CorMedix, particularly in the treatment of infectious diseases.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb is involved in the discovery and development of drugs in areas that could compete with CorMedix, including therapies for preventing and treating infections.
Novartis
NVS
Mkt Cap297.32B
Novartis AG competes with CorMedix in the global healthcare market, particularly in the development and marketing of products for the treatment of various diseases, including those targeted by CorMedix.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca is a global, science-led biopharmaceutical business that competes with CorMedix in the development and commercialization of medicines for various diseases, including infections.
Sanofi
SNY
Mkt Cap116.63B
Sanofi is a global healthcare leader that competes with CorMedix in the areas of pharmaceuticals, including the development of treatments for infections similar to those targeted by CorMedix.

About

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Show more...
CEO
Mr. Joseph Todisco MBA
Employees
64
Country
United States
ISIN
US21900C3088

Listings

0 Comments

Share your thoughts

FAQ

What is CorMedix stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange CorMedix stocks are traded under the ticker 19KA.MU.
How many employees does CorMedix have?
As of April 11, 2026, the company has 64 employees.
In which sector is CorMedix located?
CorMedix operates in the Health & Wellness sector.
When did CorMedix complete a stock split?
CorMedix has not had any recent stock splits.
Where is CorMedix headquartered?
CorMedix is headquartered in Parsippany, United States.